A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas

Trial Profile

A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Paraganglioma; Phaeochromocytoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Mar 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
    • 20 Feb 2015 New source identified and integrated (M.D. Anderson Cancer Center record:2014-0081) record.
    • 20 Feb 2015 According to the M.D. Anderson Cancer Center record, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top